Qiang YU

Education
Ph.D.	Cancer Pharmacology, Queen’s University, Kingston, Ontario, Canada (1998)
M.Sc.	Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (1991)
M.B.	Qingdao University Medical College, China (1985)

Positions
2016-present	Adjunct Professor, Faculty of Health Sciences, University of Macau
2011-present	Senior Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore
2011-present	Adjunct Professor, Department of Physiology, National University of Singapore
2011-present	Adjunct Professor, Cancer and Stem Cell Biology, DUKE-NUS
2006-2011	Adjunct Associate Professor, Department of Physiology, National University of Singapore
2006-2011	Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore
2002-2006	Senior Scientist and Principle Investigator, Cancer Biology and Pharmacology, Genome Institute of Singapore
2000-2002	Visiting Fellow Advanced Technology Center National Cancer Institute Gaithersburg, MD. USA.
1998-2001	International Fogarty Fellow Laboratory of Molecular Pharmacology, National Cancer Institute Bethesda, MD, USA
1991-1993	Research Associate, Institute of Medical Sciences, Chinese Academy of Medical Sciences

Committee and Advisory Board
2011-present	Editorial Board, Frontiers Oncology
2008-present	Associate Editor, Molecular Cancer (BioMed Central)
2007-present	Editorial Board, International Journal of Biochemistry and Cell Biology (Elsevier)
2005-2006	Management Advisory Committe, Biopolis Life Science Library

Research Interest
Cancer therapeutics and drug discovery Cancer signaling pathway modulation and drug resistance mechanisms Cancer genomics and epigenetics for drug targets and biomarker discovery

Representative Publications

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Qiang Yu “IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.” Nat Commun 2015 ; 6 : 8746 Feng M, Bao Y, Li Z, Li J, Gong M, Lam S, Wang J, Marzese DM, Donovan N, Tan EY, Hoon DS, Qiang Yu. “RASAL2 activates RAC1 to promote triple-negative breast cancer progression.” J Clin Invest , 2014 Dec;124(12):5291-304 Tan J, Li Z, Lee PL, Guan P, Aau M, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. “PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.” Cancer Discov 2013 Oct;3(10):1156-71 Shuet Theng Lee1, Min Feng, Yong Wei, Zhimei Li, Yuanyuan Qiao1, Peiyong Guan, Meiyee Aau, Xia Jiang, Chew Hooi Wong, Kelly Huynh, Jinhua Wang, Juntao Li, K. Murthy Karuturi, Ern Yu Tan, Dave SB Hoon, Yibin Kang, Qiang Yu. Protein Tyrosine Phosphatase UBASH3B is Overexpressed in Triple-Negative Breast Cancer and Promotes Invasion and Metastasis. Proc Natl Acad Sci U S A, 2013 Jul 2;110(27):11121-6 Shuet Theng Lee, Zhimei Li, Zhenlong Wu, Meiyee Aau, Peiyong Guan, R.K. Murthy Karuturi, Yih Cherng Liou and Qiang Yu .”Context-Specific Regulation of NF-kB Target Gene Expression by EZH2 in Breast Cancers”. Molecular Cell , 43, 798–810, 2011 Jing Tan, Puay Leng Lee, Zhimei Li, Xia Jiang, Yaw Chyn Lim, Shing Chuan Hooi and Qiang Yu. B55β-associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell, 18:459-471, 2010 Xiaojing Yang, Min Feng, Xia Jiang, Zhenlong Wu, Meiyee AAu, Zhimei Li, and Qiang Yu. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes & Development . 2009 23: 2388-2393 Xia Jiang, Jing Tan, Jingsong Li, Saul Kivimäe, Xiaojing Yang1 Li Zhuang, Puay Leng Lee, Mark TW. Chan, Lawrence Stanton, Edison T. Liu, Benjamin N.R.Cheyette and Qiang Yu. DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 13:529, 2008. PMID: 18538736 Jing Tan, Xiaojing Yang, Li Zhuang, Xia Jiang, Wei Chen, Puay Leng Lee, RK Murthy Karuturi, Patrick Boon Ooi Tan, Edison T. Liu and Qiang Yu. Pharmacologic disruption of Polycomb repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Development. 2007 21:1050. PMID: 17437993 Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, 4 Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y (2006). A global map of p53 transcription-factor binding sites in the human genome. Cell. 124(1):207-19. PMID: 16413492

Patents
2013	201208522-1 A Novel Reagent For Gene-Drug Therapeutics
2013	201208522-1 A Novel Reagent For Gene-Drug Therapeutics
2013	201304198-3 Rasal2 is a biomarker associated with triple negative breast cancer early relapse
2012	201107036-4 STS1 (UBASH3B) is a novel druggable target for invasive breast and prostate cancers
2010	GIS/Z05818 A biomarker for rapamycin resposne
2009	PCT/SG2009/000356 DZNep analogs as anti-cancer agents
2006	PCT/SG2006/000350 Methods for Cancer Therapy and Stem Cell Modulation
2005	PCT/SG2007/000058 Mothods for senstizing DNA Damage Response: A Potential Target for Cancer Therapy
2005	PCT/SG2006/000053 Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors
2004	PCT/SG2005/000223 Modulation of GSK-3 beta and Method of Treating Proliferative Disorders